Document Detail

A randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study.
MedLine Citation:
PMID:  17719285     Owner:  NLM     Status:  MEDLINE    
Primary intracoronary drug-eluting stent placement after the successful crossing of total coronary occlusions decreases restenosis rate at long-term follow-up compared with bare-metal stent implantation. The PRISON II trial was the first randomized study to show the safety and efficacy of sirolimus-eluting stents in patients with totally occluded native coronary arteries. The sirolimus-eluting stent is superior to the bare-metal stent in treating patients with total coronary occlusions, with significant reduction in angiographic binary in-stent and in-segment restenosis resulting in significantly reduced need for target lesion and target vessel revascularization. Whether sirolimus-eluting stents are superior to other drug-eluting stents in total coronary occlusions is unknown. In this prospective, randomized trial, sirolimus-eluting stent implantation will be compared with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. A total of 300 patients will be followed for up to 5 years with angiographic follow-up at 8 months. Quantitative coronary analysis will be performed by an independent core laboratory. The primary end point will be in-segment late luminal loss at 8 months angiographic follow-up.
Maarten J Suttorp; Gerrit J Laarman;
Related Documents :
17974015 - Analysis of arterial intimal hyperplasia: review and hypothesis.
11211165 - Serial evaluation of coronary flow reserve by transesophageal doppler echocardiography ...
11107075 - Frequency of postoperative carotid duplex surveillance and type of closure: results fro...
21072035 - Drug eluting stents for saphenous vein graft interventions.
9096945 - New double wire technique to stent ostial lesions.
15380935 - Chymase as a novel target for the prevention of vascular diseases.
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  American heart journal     Volume:  154     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-27     Completed Date:  2007-09-05     Revised Date:  2008-06-05    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  432-5     Citation Subset:  AIM; IM    
Department of Interventional Cardiology, St Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / drug therapy*
Drug Delivery Systems*
Prospective Studies
Single-Blind Method
Sirolimus / administration & dosage*,  analogs & derivatives*
Reg. No./Substance:
0/zotarolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cognitive influences on self-care decision making in persons with heart failure.
Next Document:  Left ventricular remodeling and change of systolic function after closure of patent ductus arteriosu...